Development and Testing of Nutritional Algorithms (NACHO)

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05825469
Collaborator
Cancer Nutrition Consortium Inc. (Other)
130
1
1
17
7.6

Study Details

Study Description

Brief Summary

The goal of this research study is to develop a nutrition algorithm to optimize nutritional status and improve quality of life during for participants who are completing or have completed cancer treatment.

The name of the intervention used in this research study is:

Nutrition Algorithm for Cancer Health Outcomes (NACHO) (a technology-based platform that houses the algorithms for the person-centered nutrition program)

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Nutrition Algorithm
N/A

Detailed Description

This is a longitudinal, mixed-methods, pilot descriptive study to develop a nutrition algorithm for cancer patients based on the Cancer Nutrition Consortium (CNC) study findings and refined through a dietitian panel participants and from feedback from participants and Family Advisory Council (PFAC) members.

Research study procedures include screening for eligibility, interviews and/or focus groups, dietitian panel meetings, and surveys.

Participation in this study is expected to last about 12 months.

It is expected about 130 people will participate in this research study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Development and Usability Testing of Nutrition Algorithms for Cancer Health Outcomes (NACHO) and Quality of Life During Cancer Treatment
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Nutrition Algorithm (NACHO)

Study procedures will be conducted as follows: Development of nutrition algorithm by dietitian panel participants with oncology clinician consultation via convened group meetings. Refinement of draft algorithms through feedback from participants and Family Advisory Council (PFAC) members. Baseline questionnaires for participants. Semi-structured interviews and/or focus groups with participants to evaluate algorithm usability and acceptability. Participant questionnaires.

Behavioral: Nutrition Algorithm
A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
Other Names:
  • Nutrition Algorithm for Cancer Health Outcomes (NACHO) Program
  • Outcome Measures

    Primary Outcome Measures

    1. Nutrition Algorithm [12 months]

      Primary study endpoint is development of a nutrition algorithm using the Cancer Nutrition Consortium (CNC) study findings and iteratively refine through an expert Dana-Farber Cancer Institute dietary panel along with consultations from oncology clinicians as needed and feedback from a panel of 4-6 Patient and Family Advisory Council (PFAC) members. Specific to data analyses, chi square, fisher's exact tests, and linear regression will be used to evaluate characteristics associated with changes in taste and different food preferences over time. Findings will inform the development of the algorithms.

    Secondary Outcome Measures

    1. Acceptability of Nutrition Algorithm for Cancer Health Outcomes (NACHO) Program [Up to 8 months]

      Assessed using the System Usability Scale (SUS), a 10-item instrument with scores that range from 0-100 with higher scores representing greater usability. Acceptability is defined as a SUS score of >70.

    2. Participant Satisfaction [Up to 8 months]

      Assessed using the Acceptability e-Scale (AES), a six-item scale that measures how easy, enjoyable, understandable, and helpful the intervention is. Total scores range from 6-30 with higher scores representing greater acceptability. Acceptability is defined as a AES score of >24.

    3. Panel member characteristics (Aims 1a, 1b, 2a, 2b) - Age [Up to 12 months]

      Age group (i.e., 18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+)

    4. Panel member characteristics (Aims 1a, 1b, 2a, 2b) - Gender identity [Up to 12 months]

      Gender identity (i.e., female, male, other____, prefer not to answer)

    5. Panel member characteristics (Aims 1a, 1b, 2a, 2b) - Ethnicity [Up to 12 months]

      Ethnicity (i.e., Hispanic/Latinx / non-Hispanic/non-Latinx, prefer not to answer)

    6. Panel member characteristics (Aims 1a, 1b, 2a, 2b) - Race [Up to 12 months]

      Race (i.e., Black, Caucasian, Asian, Native American, Pacific Islander, Alaska Native, multiracial, prefer not to answer)

    7. Panel member characteristics (Aims 1a, 1b, 2a, 2b) - Position [Up to 12 months]

      Position / role and years in position (non-patient panel members only) (fill in)

    8. Characteristics of the cohort of 100 patients (Aim 3) - Age [Up to 12 months]

      Age group (i.e., 18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+)

    9. Characteristics of the cohort of 100 patients (Aim 3) - Gender identity [Up to 12 months]

      Gender identity (i.e., female, male, other____, prefer not to answer)

    10. Characteristics of the cohort of 100 patients (Aim 3) - ethnicity [Up to 12 months]

      Ethnicity (i.e., Hispanic/Latinx / non-Hispanic/non-Latinx, prefer not to answer)

    11. Characteristics of the cohort of 100 patients (Aim 3) - race [Up to 12 months]

      Race (i.e., Black, Caucasian, Asian, Native American, Pacific Islander, Alaska Native, multiracial, prefer not to answer)

    12. Characteristics of the cohort of 100 patients (Aim 3) - BMI [Up to 12 months]

      Body mass index will will be calculated from weight in pounds and height in inches using the formula: weight (lb) / [height (in)]squared x 703

    13. Characteristics of the cohort of 100 patients (Aim 3) - Comorbidities [Up to 12 months]

      Comorbidities: Number of comorbidities (e.g., heart disease, diabetes) will be abstracted from electronic health records

    14. Global Health [Up to 12 months]

      PROMIS-10 Global Health Questionnaire v.1.2 is an NIH-developed, valid and reliable instrument that will be used to assess functional status and quality of life. Higher scores represent better health. Scores will be computed to identify global physical and mental health component scores. Participant patients will complete this assessment at baseline, 2 months, and 5 months (visits 1, 3, and 6, respectively). T-scores will be used in the analysis to identify characteristics associated with other participant patients at the same global health levels. Changes in T-scores over time will be compared with changes in BMI and associated with utilization of the nutrition algorithm.

    15. Symptom Questions [Up to 12 months]

      Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAETM) will be used to collect data on the occurrence, severity, and level of interference with daily activities for sleep quality (i.e., insomnia), pain, fatigue, and depression (i.e., anxiety, discouraged, sad) at baseline, 2 months, and 5 months (respectively visits 1, 3, and 6). Higher scores will indicate worse symptom experiences. T-scores will be used in the analysis to identify characteristics associated with other participant patients at the same global health levels. Changes in T-scores over time will be compared with changes in BMI and associated with utilization of the nutrition algorithm.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria for Dietitians/Oncology clinicians - Have worked with at least 3 patients at the study site who had nutritional challenges

    Inclusion Criteria for Patient and Family Advisory Council (PFAC) participants

    • Current member of adult PFAC

    • 18 years old

    Inclusion Criteria for Patient participants

    • 18 years old

    • Able to speak and read English

    • Completed primary treatment (aim 2b) or actively undergoing treatment (aim 2b and aim 3, exploratory)

    • Access to a device (e.g., computer, tablet, smartphone) through which they can receive and engage with a REDCap link

    Exclusion Criteria for Patient Participants

    • Provider does not recommend

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dana Farber Cancer Institute Boston Massachusetts United States 02115

    Sponsors and Collaborators

    • Dana-Farber Cancer Institute
    • Cancer Nutrition Consortium Inc.

    Investigators

    • Principal Investigator: Marilyn Hammer, MD, Dana-Farber Cancer Institute

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Marilyn Hammer, PhD, Principal Investigator, Dana-Farber Cancer Institute
    ClinicalTrials.gov Identifier:
    NCT05825469
    Other Study ID Numbers:
    • 22-637
    First Posted:
    Apr 24, 2023
    Last Update Posted:
    Apr 24, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Marilyn Hammer, PhD, Principal Investigator, Dana-Farber Cancer Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 24, 2023